

Product Name	: Rigosertib sodium
Synonyms	: ON-01910 sodium; ON01910 sodium; ON01910 sodium
Cat No.	: M15194
CAS Number	: 592542-60-4
Molecular Formula	: C ₂₁ H ₂₄ NNaO ₈ S
Formula Weight	: 473.47
Chemical Name	: Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, sodium salt (1:1)
Description	Rigosertib sodium (ON 01910.Na) is a potent, non-ATP-competitive PLK1 inhibitor (IC₅₀=9-10 nM), selectively induces mitotic G2/M arrest and apoptosis in cancer cells; also exhibits inhibitory activity against PDGFR, Abl, and Flt-1, at higher concentrations, inhibits CDK1, Plk2, Src, and Fyn; demonstrates in vitro cytotoxicity against DU145 and K562 cells with IC₅₀ of 100 and 15 nM; potently inhibits tumor growth in a variety of xenograft nude mouse models, does not exhibit hematotoxicity, liver damage, or neurotoxicity shows strong synergy with several chemotherapeutic agents. Blood Cancer Phase 3 Clinical
Pathway	: Cell Cycle/DNA Damage
Target	: PLK
Receptor	: PLK
Solubility	: H ₂ O: ≥ 52 mg/mL
SMILES	: <chem>COC1=CC(=C(C=C1)CS(=O)(=O)C=CC2=C(C=C(C=C2OC)OC)OC)NCC(=O)[O-].[Na+]</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Reddy MV, et al. J Med Chem. 2011 Sep 22;54(18):6254-76. | 2. Gumireddy K, et al. Cancer Cell. 2005 Mar;7(3):275-86. | 3. Oussenko IA, et al. Cancer Res. 2011 Jul 15;71(14):4968-76. | 4. Chun AW, et al. Cancer Chemother Pharmacol. 2009 Dec;65(1):177-86.